Coronavirus vaccine developed in China shows promise after early study in 100 people

0
509

A potential coronavirus vaccine developed in China appeared safe and able to generate an immune response after an early trial in more than 100 people, according to a new study.

The vaccine, called Ad5-nCoV, is being developed by the Chinese company CanSino Biologics, and was one of the first coronavirus vaccines to enter early human trials back in March. Now, there are more than 100 different coronavirus vaccines in development worldwide, with at least eight of those in the process of human trials.

Ad5-nCoV uses a weakened version of a common cold virus (known as an adenovirus) — which infects human cells but doesn’t cause disease — to deliver a fragment of genetic material from SARS-CoV-2, the virus that causes COVID-19. This genetic material provides instructions for making the “spike protein” on the surface of SARS-CoV-2. The idea is that a person’s immune system will create antibodies against the spike protein, which will help fight off the coronavirus if the person is later exposed to it.

In the new study, published Friday (May 22) in the journal The Lancet, the researchers tested Ad5-nCoV in 108 healthy people ages 18 to 60 who didn’t have COVID-19. Participants received either a low, middle or high dose of the vaccine.

Two weeks after vaccination, participants in all three groups showed some level of an immune response to the virus. By 28 days, nearly all participants had developed antibodies that bound to SARS-CoV-2 (but don’t necessarily attack the virus), and about half of the participants in the low- and middle- dose groups and three-quarters of participants in the high-dose group developed “neutralizing antibodies,” which bind to and disable the virus to prevent it from infecting cells.

The most common side effects were mild pain at the injection site, mild fever, fatigue, headache and muscle pain, the study said.

However, nine participants (two in the low dose group, two in the middle dose group and five in the high dose group) developed a fever of more than 101 degrees Fahrenheit (38.5 degrees Celsius), and one participant in the high dose group developed a high fever along with fatigue, shortness of breath  and muscle pain. However these effects lasted no more than 48 hours.

Participants were aware of which dose they received, which may have affected their perceptions of the side effects, according to The New York Times.

“These results represent an important milestone,” study senior author Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, said in a statement “However, these results should be interpreted cautiously. The challenges in the development of a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19.”

The researchers have now started a larger, phase 2 study of the vaccine involving 500 participants who will be given a low or intermediate dose of the vaccine, or a placebo. This study will also include participants over 60 years old, and will look at side effects up to six months after vaccination.

Several other coronavirus vaccine candidates reported promising developments this week. On Monday (May 18), biotech company Moderna announced that 45 volunteers who received doses of its vaccine candidate, called mRNA-1273, developed antibodies within 15 days, and that the  level of antibodies seen in their blood was comparable to that seen in people who have recovered from COVID-19, Live Science previously reported.

In addition, researchers at Oxford University announced that their vaccine candidate, called ChAdOx1-nCov19, will now be tested in advanced clinical trials involving more than 10,000 people, and doses could be available as early as this September, according to NBC News.

About VT Editors
VT Editors is a General Posting account managed by Jim W. Dean and Gordon Duff. All content herein is owned and copyrighted by Jim W. Dean and Gordon Duff
ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy